drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
An allogeneic, off-the-shelf CAR T-cell therapy enriched for T stem cell memory (Tscm) cells. These engineered T cells express a dual CAR targeting CD19 and CD20 on B cells to drive activation, proliferation, and cytotoxic killing of malignant B cells. Administered as a single IV dose after lymphodepletion; the Tscm phenotype is intended to enhance persistence and self-renewal.
nci_thesaurus_concept_id
C201791
nci_thesaurus_preferred_term
Allogeneic CD19/CD20-specific CAR-T Cells P-CD19CD20-ALLO1
nci_thesaurus_definition
An off-the-shelf (OTS) preparation of human allogeneic T-lymphocytes containing primarily stem cell memory T-cells (Tscm) that have been genetically modified to express two chimeric antigen receptors (CARs) targeting the tumor-associated antigens (TAAs) CD19 and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic CD19/CD20-specific CAR-T cells P-CD19CD20-ALLO1 specifically recognize and induce selective toxicity in CD19- and/or CD20-expressing tumor cells. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic T cells enriched for T stem cell memory are engineered to express dual CARs targeting CD19 and CD20 on B cells. Antigen binding activates T-cell signaling leading to proliferation and cytotoxic killing of malignant B cells; dual targeting aims to limit antigen escape, while the Tscm phenotype supports persistence and self-renewal. Given after lymphodepletion; an optional rimiducid safety switch can induce rapid ablation of the cells if required.
drug_name
P-CD19CD20-ALLO1
nct_id_drug_ref
NCT06014762